Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. Academic Article uri icon

Overview

abstract

  • Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.

publication date

  • January 1, 1994

Research

keywords

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • Graft Survival
  • Heart Transplantation
  • Receptors, Immunologic

Identity

PubMed Central ID

  • PMC2191341

Scopus Document Identifier

  • 0028069390

Digital Object Identifier (DOI)

  • 10.1084/jem.179.1.341

PubMed ID

  • 7903681

Additional Document Info

volume

  • 179

issue

  • 1